Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Tiling path genomic profiling of grade 3 invasive ductal breast cancers.

Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS.

Clin Cancer Res. 2009 Apr 15;15(8):2711-22. doi: 10.1158/1078-0432.CCR-08-1878. Epub 2009 Mar 24.

2.

Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS.

J Pathol. 2010 Nov;222(3):282-98. doi: 10.1002/path.2763.

PMID:
20815046
3.

Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.

Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS.

J Pathol. 2008 Aug;215(4):398-410. doi: 10.1002/path.2368.

PMID:
18484683
4.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.

PMID:
22015727
6.

An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.

Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS.

Breast Cancer Res Treat. 2010 Jun;121(3):575-89. doi: 10.1007/s10549-009-0501-3. Epub 2009 Aug 18.

PMID:
19688261
7.

Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.

Marchiò C, Iravani M, Natrajan R, Lambros MB, Geyer FC, Savage K, Parry S, Tamber N, Fenwick K, Mackay A, Schmitt FC, Bussolati G, Ellis I, Ashworth A, Sapino A, Reis-Filho JS.

J Pathol. 2009 Jul;218(3):301-15. doi: 10.1002/path.2572.

PMID:
19479727
8.

BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.

Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP.

Am J Surg Pathol. 2007 Jan;31(1):121-8.

PMID:
17197928
9.

Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.

Rosenthal SI, Depowski PL, Sheehan CE, Ross JS.

Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):40-6.

PMID:
11893034
10.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
11.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
12.

Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.

Yoder BJ, Wilkinson EJ, Massoll NA.

Breast J. 2007 Mar-Apr;13(2):172-9. Review.

PMID:
17319859
13.

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.

Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martín-Guijarro Mdel C, Hernandez L, Palacios J.

Am J Surg Pathol. 2007 Apr;31(4):501-8.

PMID:
17414096
14.

Molecular grading of ductal carcinoma in situ of the breast.

Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS.

Clin Cancer Res. 2008 Dec 15;14(24):8244-52. doi: 10.1158/1078-0432.CCR-08-0939.

15.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
16.

The genomic profile of HER2-amplified breast cancers: the influence of ER status.

Marchiò C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS.

J Pathol. 2008 Dec;216(4):399-407. doi: 10.1002/path.2423.

PMID:
18810758
17.

Prognostic relevance of gene amplifications and coamplifications in breast cancer.

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G.

Cancer Res. 2004 Dec 1;64(23):8534-40.

18.

Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.

Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ.

Cancer Res. 2006 May 15;66(10):5278-86.

19.
20.

In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.

Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ.

Cancer. 2000 Dec 1;89(11):2153-60.

PMID:
11147584
Items per page

Supplemental Content

Write to the Help Desk